NEVRO CORP. (NYSE:NVRO) Files An 8-K Other EventsItem 8.01
On December 9, 2016, Nevro Corp. (“Nevro”) announced that Boston Scientific Corp. and Boston Scientific Neuromodulation Corp. (collectively, “Boston Scientific”) have filed a patent infringement lawsuit alleging Nevro’s manufacture, use and sale of the Senza® system infringes certain of Boston Scientific’s patents covering technology related to stimulation leads, batteries and telemetry units. The lawsuit, filed in the United States District Court for the District of Delaware, seeks unspecified damages and attorney’s fees, as well as preliminary and permanent injunctive relief against further infringement.
On November 28, 2016, Nevro filed a patent lawsuit against Boston Scientific asserting Boston Scientific infringes Nevro’s patents covering its groundbreaking Senza® system and HF10™ therapy.
About NEVRO CORP. (NYSE:NVRO)
Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals. The Company’s Senza is designed to create electrical impulses from 2 hertz to 10 kilohertz (kHz), including its HF10 therapy. HF10 therapy delivers waveforms at 10 kHz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads, a trial stimulator, an implantable pulse generator (IPG), surgical tools, a clinician laptop programmer, a patient remote control and a mobile charger. NEVRO CORP. (NYSE:NVRO) Recent Trading Information
NEVRO CORP. (NYSE:NVRO) closed its last trading session down -1.88 at 76.38 with 425,857 shares trading hands.
